CA-C3-AI
16.2.2021 22:29:13 CET | Business Wire | Press release
C3 AI (NYSE:AI), a leading enterprise AI software provider, today announced the release of major enhancements to its enterprise AI application development platform and AI applications designed to further accelerate digital transformation. Over the past decade, C3 AI has invested continuously in the C3 AI® Suite, its open, secure, and multi-cloud enterprise AI platform that leverages a model-driven architecture, enabling end-to-end enterprise AI including data integration, model development, MLOps, application development, and model governance and maintenance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006166/en/
The latest release – Version 7.17 – provides new capabilities to track and manage full lineage from data sources to application entities. In addition, the latest release includes new composable machine learning (ML) pipelines for data scientists; enhancements to C3 AI CRM, C3 AI Anti-Money Laundering, C3 AI Energy Management, C3 AI Production Schedule Optimization, and C3 AI Reliability applications; and a new enterprise AI application for the oil and gas industry, C3 AI Well Development Optimization.
“Today’s release introduces even more market-leading features for developers, data scientists, and data engineers, while bringing unparalleled speed to the development of enterprise AI applications,” said C3 AI President and Chief Product Officer Houman Behzadi. “We continue to invest significantly in our enterprise AI platform, wide range of developer tools, and configurable enterprise AI applications to enable a richer and more cohesive developer and user experience to accelerate AI adoption.”
The latest platform enhancements and features available with the C3 AI Suite include:
- Comprehensive data, feature, and model lineage: Improvements to enterprise AI application development tools include a new comprehensive data, feature, and model lineage component that enables developers and end users to understand the lineage of their application and AI/ML results.
- Enhanced time series feature generation: The latest release significantly accelerates feature engineering and model development. Enhancements enable faster feature parameterization, more comprehensive statistical transformations, and improved feature selection for use in C3 AI ML Pipelines.
- New composable ML pipelines: Expanding the ever-growing library of C3 AI ML Pipelines, the latest release includes four new pipelines to accelerate model development, including a deep learning pipe for forecasting and a linear quantile regression pipe for probabilistic predictions. C3 AI ML Pipelines also deliver improved model interpretability support with the addition of SHAP (Shapley Additive Explanations) to the available explainability frameworks.
- Multi-cloud Kubernetes service: As part of the ongoing Kubernetes/OpenShift standardization, the latest release supports the Kubernetes service on all clouds.
- New prebuilt data connectors: Performance and scalability improvements to C3 AI’s Virtual Data Lake framework include connectors to Snowflake, Spark/Databricks, S3, Microsoft Power BI, Azure Data Lake, and Microsoft Dynamics 365 – further expanding the library of prebuilt data connectors on the C3 AI Suite. The new connectors help accelerate data integration and allow engineers to create a virtual data image or ingest data directly into the C3 AI Suite.
- Enhancements to enterprise object models: New additions and enhancements to C3 AI’s suite of prebuilt enterprise object models further accelerate development of AI applications. Cross-industry object models provide functional capabilities, including energy management, equipment and process reliability, fraud detection, inventory optimization, and manufacturing yield optimization. In addition, C3 AI also offers industry-specific object models for manufacturing, financial services, oil and gas, utilities, and defense.
C3 AI also continues to invest in its growing portfolio of enterprise AI applications. Notable enhancements include:
- C3 AI CRM delivers a new AI-based precision revenue forecasting and opportunity scoring feature leveraging both data in traditional CRM systems and external feeds (e.g., financial data, news, commodity prices).
- C3 AI Reliability enhancements include a new module – C3 AI Diagram Parsing – to automatically generate digital twins and object models from piping and instrumentation diagrams (P&IDs). C3 AI Diagram Parsing uses machine vision and natural language processing to parse P&IDs to generate machine-readable asset hierarchies and sensor-to-asset mappings.
- C3 AI Inventory Optimization enhancements include what-if scenario modeling capabilities for inventory analysts to account for the ever-changing dynamics of globally distributed supply chains and optimize for the best operating outcomes.
- C3 AI Production Schedule Optimization enhancements include a new user interface, enhancements to the object model, and additional composable ML pipelines. Modifications to the user interface enable end users to more easily generate, review, and act on AI-based demand forecasts and order line recommendations. The newly available demand planning and scheduling data models and ML pipelines help accelerate model development and deployment for data science teams.
- C3 AI Well Development Optimization is a new oil and gas application that optimizes upstream drilling costs and mitigates non-productive time risks such as stuck pipe, lost circulation, and drilling recovery. The application provides the foundational data model for AI-enabled well development applications, as well as for upstream oil and gas operators to plan and execute drilling operations.
For more information about this new release, please contact sales@c3.ai .
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom